These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 24613489)

  • 1. An empirical model for dissolution profile and its application to floating dosage forms.
    Weiss M; Kriangkrai W; Sungthongjeen S
    Eur J Pharm Sci; 2014 Jun; 56():87-91. PubMed ID: 24613489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of anti-tacking agents on properties of gas-entrapped membrane and effervescent floating tablets.
    Kriangkrai W; Puttipipatkhachorn S; Sriamornsak P; Pongjanyakul T; Sungthongjeen S
    AAPS PharmSciTech; 2014 Dec; 15(6):1357-69. PubMed ID: 24927669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling accelerated and decelerated drug release in terms of fractional release rate.
    Weiss M
    Eur J Pharm Sci; 2015 Feb; 68():51-5. PubMed ID: 25486334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanistic evaluation of binary effects of magnesium stearate and talc as dissolution retardants at 85% drug loading in an experimental extended-release formulation.
    Dürig T; Fassihi R
    J Pharm Sci; 1997 Oct; 86(10):1092-8. PubMed ID: 9344163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of artificial neural networks to predict drug dissolution profiles and evaluation of network performance using similarity factor.
    Peh KK; Lim CP; Quek SS; Khoh KH
    Pharm Res; 2000 Nov; 17(11):1384-8. PubMed ID: 11205731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo evaluation of two new sustained release formulations elaborated by one-step melt granulation: level A in vitro-in vivo correlation.
    Ochoa L; Igartua M; Hernández RM; Solinís MA; Gascón AR; Pedraz JL
    Eur J Pharm Biopharm; 2010 Jun; 75(2):232-7. PubMed ID: 20159037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of dissolution profiles of theophylline extended-release dosage forms.
    Wolny D; Gruchlik A; Chodurek E; Szara M; Dzierzewicz Z
    Acta Pol Pharm; 2012; 69(6):1384-6. PubMed ID: 23285707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Theophylline loaded gastroretentive floating tablets based on hydrophilic polymers: preparation and in vitro evaluation.
    Khan F; Ibn Razzak SM; Khan ZR; Azad MA; Chowdhury JA; Reza S
    Pak J Pharm Sci; 2009 Apr; 22(2):155-61. PubMed ID: 19339225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained release dosage forms dissolution behavior prediction: a study of matrix tablets using NIR spectroscopy.
    Tabasi SH; Moolchandani V; Fahmy R; Hoag SW
    Int J Pharm; 2009 Dec; 382(1-2):1-6. PubMed ID: 19660535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation of delayed release tablet dosage forms by compression coating: effect of coating material on theophylline release.
    El-Malah Y; Nazzal S
    Pharm Dev Technol; 2010 Jun; 15(3):305-10. PubMed ID: 22716471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formulation and in-vitro evaluation of floating bilayer tablet of lisinopril maleate and metoprolol tartrate.
    Ijaz H; Qureshi J; Danish Z; Zaman M; Abdel-Daim M; Hanif M; Waheed I; Mohammad IS
    Pak J Pharm Sci; 2015 Nov; 28(6):2019-25. PubMed ID: 26639495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eudraginated polymer blends: a potential oral controlled drug delivery system for theophylline.
    Emeje M; John-Africa L; Isimi Y; Kunle O; Ofoefule S
    Acta Pharm; 2012 Mar; 62(1):71-82. PubMed ID: 22472450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissolution profile of theophylline modified release tablets, using a biorelevant Dynamic Colon Model (DCM).
    Stamatopoulos K; Batchelor HK; Simmons MJH
    Eur J Pharm Biopharm; 2016 Nov; 108():9-17. PubMed ID: 27531624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the absorption of theophylline from immediate- and controlled-release dosage forms with a numerical approach using the in vitro dissolution-permeation process using caco-2 cells.
    Noureddine N; Zerrouk N; Nicolis I; Allain P; Sfar S; Chaumeil JC
    Drug Dev Ind Pharm; 2005 May; 31(4-5):397-404. PubMed ID: 16093205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study of dissolution characteristics of polymeric and wax granulations of theophylline and their tablets.
    Uhumwangho MU; Okor RS
    Pak J Pharm Sci; 2008 Jul; 21(3):230-6. PubMed ID: 18614417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of Dissolution Profiles From Process Parameters, Formulation, and Spectroscopic Measurements.
    Zhao Y; Li W; Shi Z; Drennen JK; Anderson CA
    J Pharm Sci; 2019 Jun; 108(6):2119-2127. PubMed ID: 30742835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of HPMC concentration on release of theophylline or hydrocortisone from extended release mini-tablets.
    Mohamed FA; Roberts M; Seton L; Ford JL; Levina M; Rajabi-Siahboomi AR
    Drug Dev Ind Pharm; 2013 Aug; 39(8):1167-74. PubMed ID: 22540355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wax-based sustained release matrix pellets prepared by a novel freeze pelletization technique II. In vitro drug release studies and release mechanisms.
    Cheboyina S; Wyandt CM
    Int J Pharm; 2008 Jul; 359(1-2):167-73. PubMed ID: 18495391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative evaluation using in vitro dissolution tests of various sustained release theophylline preparations].
    Kissné CE
    Acta Pharm Hung; 1990 Nov; 60(5-6):191-6. PubMed ID: 2087990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo sustained-release characteristics of theophylline matrix tablets and novel cluster tablets.
    Hayashi T; Kanbe H; Okada M; Kawase I; Ikeda Y; Onuki Y; Kaneko T; Sonobe T
    Int J Pharm; 2007 Aug; 341(1-2):105-13. PubMed ID: 17512147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.